161 related articles for article (PubMed ID: 36153381)
1. Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer.
Inoue Y; Fujishima M; Ono M; Masuda J; Ozaki Y; Maeda T; Uehiro N; Takahashi Y; Kobayashi T; Sakai T; Osako T; Ueno T; Ohno S
Breast Cancer Res Treat; 2022 Nov; 196(2):341-348. PubMed ID: 36153381
[TBL] [Abstract][Full Text] [Related]
2. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.
Xu J; Ni C; Ma C; Zhang L; Jing X; Li C; Liu Y; Qu X
Clin Transl Oncol; 2017 Aug; 19(8):989-996. PubMed ID: 28247194
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
[No Abstract] [Full Text] [Related]
4. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
[TBL] [Abstract][Full Text] [Related]
6. Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study.
Sawa A; Bando H; Kamohara R; Takeuchi N; Terasaki A; Okazaki M; Iguchi-Manaka A; Hara H
Oncology; 2022; 100(11):591-601. PubMed ID: 36099888
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
8. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil to lymphocyte ratio is a prognostic factor for disease free survival in patients with breast cancer underwent curative resection.
Geng SK; Fu SM; Fu YP; Zhang HW
Medicine (Baltimore); 2018 Aug; 97(35):e11898. PubMed ID: 30170382
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment Absolute Lymphocyte Count and Neutrophil-to-lymphocyte Ratio Are Prognostic Factors for Stage III Breast Cancer.
Yamanouchi K; Maeda S; Takei D; Koga Y; Yamashita M; Hamada T; Hirayama T; Yoneda A; Tokunaga T; Takeshita H; Kuroki T
Anticancer Res; 2021 Jul; 41(7):3625-3634. PubMed ID: 34230159
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical utility between neutrophil count and neutrophil-lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review.
Komura N; Mabuchi S; Yokoi E; Kozasa K; Kuroda H; Sasano T; Matsumoto Y; Kimura T
Int J Clin Oncol; 2018 Feb; 23(1):104-113. PubMed ID: 28951992
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer.
Shao B; Liu X; Li H; Song G; Di L; Jiang H; Yan Y; Zhang R; Ran R; Zhang J; Liu Y; Wang H; Wang J
Curr Oncol; 2022 Aug; 29(9):6154-6166. PubMed ID: 36135052
[TBL] [Abstract][Full Text] [Related]
13. Preoperative neutrophil-to-lymphocyte ratio is a more valuable prognostic factor than platelet-to-lymphocyte ratio for nonmetastatic rectal cancer.
Li H; Song J; Cao M; Wang G; Li L; Zhang B; Li Y; Xu W; Zheng J
Int Immunopharmacol; 2016 Nov; 40():327-331. PubMed ID: 27664571
[TBL] [Abstract][Full Text] [Related]
14. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
15. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?
Dirican A; Kucukzeybek BB; Alacacioglu A; Kucukzeybek Y; Erten C; Varol U; Somali I; Demir L; Bayoglu IV; Yildiz Y; Akyol M; Koyuncu B; Coban E; Ulger E; Unay FC; Tarhan MO
Int J Clin Oncol; 2015 Feb; 20(1):70-81. PubMed ID: 24532163
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in older patients with metastatic cancer.
Chen KH; Tsang NM; Chou WC; Tai SF; Liu SC; Lei KF; Chang KP; Chuang WC; Pai PC
J Geriatr Oncol; 2019 Sep; 10(5):757-762. PubMed ID: 31085137
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
Grassadonia A; Graziano V; Iezzi L; Vici P; Barba M; Pizzuti L; Cicero G; Krasniqi E; Mazzotta M; Marinelli D; Amodio A; Natoli C; Tinari N
Cells; 2021 Jul; 10(7):. PubMed ID: 34359855
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer.
Miyahara Y; Takashi S; Shimizu Y; Ohtsuka M
World J Surg Oncol; 2020 Apr; 18(1):78. PubMed ID: 32321522
[TBL] [Abstract][Full Text] [Related]
19. Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence.
Moon G; Noh H; Cho IJ; Lee JI; Han A
Breast Cancer; 2020 Jan; 27(1):54-61. PubMed ID: 31280452
[TBL] [Abstract][Full Text] [Related]
20. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
